^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Ovarian Cancer
    Drug:avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) +
    defactinib (VS-6063) (FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Trial of Defactinib and VS-6766.

    Excerpt:
    ...Histologically or cytologically proven advanced non-small-cell lung cancer (NSCLC) with a documented KRAS mutation, refractory to conventional treatment, or for which...
    Trial ID:
    FRAME
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    1425 - Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumors

    Published date:
    03/10/2021
    Excerpt:
    ...the combination of VS-6766 with defactinib showed clinical activity in low grade serous ovarian cancer (LGSOC; ORR = 56% in KRAS-G12 mt and ORR = 41% in all 17 LGSOC patients; 8/17/20 data cut off).